# US 2026/0097095 A1 · Pegylated reconstituted high-density lipoprotein nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097095 A1
- Document ID: US20260097095A1
- Status: Published application
- Kind: A1
- Application number: 19/355,472
- Filed: 2025-10-10
- Published: 2026-04-09
- Earliest claimed: 2023-05-04
- Assignees: Mepsgen Co., Ltd.
- Applicants: Mepsgen Co., Ltd.
- Inventors: Wooseung LEE; Jin KIM; Yong Tae KIM
- Web page: https://patentgrep.com/patent/US20260097095A1

## CPC

- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases are provided. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.

## Claims

### Claim 1

A PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle comprising a PEGylated lipid, a phospholipid, and apolipoprotein E, wherein the synthetic mixing molar ratio of the apolipoprotein E and the PEGylated lipid is 1:0.5 to 1:50.

### Claim 2 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the synthetic mixing molar ratio of the apolipoprotein E and the PEGylated lipid is 1:1 to 1:10.

### Claim 3 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the synthetic mixing molar ratio of the apolipoprotein E and the PEGylated lipid is 1:1 to 1:5.

### Claim 4 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the average molecular weight of the polyethylene glycol in the PEGylated lipid is 550 to 5,000.

### Claim 5 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the average molecular weight of the polyethylene glycol in the PEGylated lipid is 1,000 to 2,000.

### Claim 6 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle has a size of 5 to 50 nm.

### Claim 7 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle has a size of 10 to 35 nm.

### Claim 8 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the apolipoprotein E is apolipoprotein E2, E3, or E2 and E3.

### Claim 9 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle may further comprise apolipoprotein A1.

### Claim 10 (depends on 1)

The PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticle according to claim 1, wherein the phospholipid is at least one selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), egg phosphatidylcholine (EPC), dilauroylphosphatidylcholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), 1-myristoyl-2-palmitoylphosphatidylcholine (MPPC), 1-palmitoyl-2-myristoylphosphatidylcholine (PMPC), 1-palmitoyl-2-stearoylphosphatidylcholine (PSPC), 1-stearoyl-2-palmitoyl phosphatidylcholine (SPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DAPC), 1,2-diarachidoyl-sn-glycero-3-phosphocholine (DBPC), 1,2-diicosanoyl-sn-glycero-3-phosphocholine (DEPC), palmitoyloleoylphosphatidylcholine (POPC), lysophosphatidylcholine, dilinoleoylphosphatidylcholine, distearoylphosphatidylethanolamine (DSPE), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), palmitoyloleoylphosphatidylethanolamine (POPE), lysophosphatidylethanolamine, N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide) (VL-5), dioctadecylamidoglycylspermine 4-trifluoroacetic acid (DOGS), 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DCChol), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleyl-3-trimethylammonium-propane (DOTAP), (1,2-dioleyloxypropyl)-3-dimethylhydroxyethyl ammonium bromide (DORIE), 1,2-dimyristyloxy-propyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE), 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propaneammonium bromide (GAP-DLRIE), N-t-butyl-N′-tetradecyl-3-tetradecylaminopropionamidine (diC14-amidine), ethylphosphocholine (Ethyl PC), dimethyldioctadecylammonium bromide (DDAB), N4-cholesteryl-spermine (GL67), 1,2-dioleyloxy-3-dimethylaminopropane (DODMA), D-Lin-MC3-DMA (MC3, DLin-MC3-DMA), DLin-KC2-DMA, and DLin-DMA.

### Claim 11 (depends on 1)

A composition for preventing or treating neurodegenerative diseases, comprising the PEGylated reconstituted high-density lipoprotein nanoparticles according to claim 1.

### Claim 12 (depends on 11)

The composition for preventing or treating neurodegenerative diseases according to claim 11, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Pick's disease, Huntington's disease, Creutzfeldt-Jakob disease, Lou Gehrig's disease, spinocerebellar degeneration, spinocerebellar ataxia, prion disease, cognitive dysfunction, senile dementia, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, alcoholic dementia, presenile dementia, Machado-Joseph disease, dystonia, multiple system atrophy, progressive supranuclear palsy, Friedreich's ataxia, and temporal lobe epilepsy.

### Claim 13 (depends on 11)

The composition for preventing or treating neurodegenerative diseases according to claim 11, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 14

A method for producing PEGylated reconstituted high-density lipoprotein (rHDL) nanoparticles comprising a PEGylated lipid, a phospholipid, and apolipoprotein E, wherein the method comprises:
a step of injecting a phospholipid and PEGylated lipid solution into a second inlet located in the center of a microfluidic device comprising three inlets and one outlet, and
a step of injecting high-density lipoprotein (HDL) or reconstituted high-density lipoprotein (rHDL) comprising an apolipoprotein and a phospholipid into the first and third inlets located on either side.
